Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2009 Nov;8(11):1513-26. doi: 10.1586/erv.09.108.

HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.

Author information

  • 1Division of Melanoma and Muscle-Cutaneous Sarcomas, IEO, European Institute of Oncology, Milan, Italy. giulio.tosti@ieo.it

Abstract

Heat-shock proteins are highly conserved, stress-induced proteins with chaperone function for trafficking and delivering peptides within the different compartments of the cell. Tumor-derived heat-shock protein-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, the HSPPC-96-based vaccine vitespen (formerly Oncophage) is the first autologous cancer vaccine made from individual patients' tumors that has shown encouraging results in clinical trials. In Phase I and II clinical trials, this vaccine has shown activity on different malignancies, such as gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukemia. In Phase III clinical trials in melanoma and kidney cancer, it demonstrated an excellent safety profile with almost no toxicity. Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management.

PMID:
19863242
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk